HNF1 homeobox A (hepatocyte nuclear factor 1 homeobox A), also known as HNF1A, is a human gene on chromosome 12.[1][2][3] It is ubiquitously expressed in many tissues and cell types.[4] The protein encoded by this gene is a transcription factor that is highly expressed in the liver and is involved in the regulation of the expression of several liver-specific genes.[5] Mutations in the HNF1A gene have been known to cause diabetes.[6] The HNF1A gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.[7]
This protein belongs to the HNF1 homeobox family.[8] It contains 3 functional domains: an N-terminaldimerization domain (residues 1–32), a bipartite DNA-binding motif containing an atypical POU-homeodomain (residues 98–280), and a C-terminal transactivation domain (residues 281–631).[9][10] There is also a flexible linker (residues 33–97) which connects the dimerization and DNA binding domains.[10] Crystal structures have been solved for the dimerization domain, which forms a four-helix bundle where two α helices are separated by a turn; the DNA-binding motif, which forms a helix-turn-helix structure; and the POU-homeodomain, which is composed of three α helices, contained in the motif. This homeodomain is considered atypical due to an extended loop inserted between the second and third helices relative to the canonical homeodomain fold. The atypical insertion is thought to stabilize the interface to improve transcriptional efficiency.[9] Meanwhile, the dimerization domain is responsible for the homo- and heterodimerization of HNF-1α. The resulting dimer contains a rigid “mini-zipper”, comprising α-helices 1 and 1′, linked by a non-canonical tight turn to a flexible C-terminal comprising α-helices 2 and 2′.[10]
In humans, mutations in HNF1A cause diabetes that responds to low dose sulfonylurea agents.[26] The identification of extreme sulfonylurea sensitivity in patients with diabetes mellitus owing to heterozygous mutations in HNF1A presents a clear example of the relevance of HNF1A in diabetes patients and how pharmacogenetics can contribute in patient care.[27] For example, patients with maturity onset diabetes of the young owing to mutations in HNF1A (which accounts for ~3% of all diabetes mellitus cases diagnosed under the age of 30 years) are extremely sensitive to sulfonylurea treatment and can successfully transition off insulin treatment.[6] Likewise, patients with diabetes caused by mutations in the HNF1A gene have been described as sensitive to the hypoglycemic effects of sulphonylureas. The cause of hyperglycemia appears to alter the response to hypoglycemic drugs. Accordingly, HNF-1α-induced diabetes has marked sulphonylurea sensitivity. This pharmacogenetic effect is consistent with models of HNF-1α deficiency, and the genetic basis of hyperglycemia may have implications for patient management.[6]
Clinical Marker
A multi-locus genetic risk score study based on a combination of 27 loci, including the HNF1A gene, identified individuals at increased risk for both incident and recurrent coronary artery disease events, as well as an enhanced clinical benefit from statin therapy. The study was based on a community cohort study (the Malmo Diet and Cancer study) and four additional randomized controlled trials of primary prevention cohorts (JUPITER and ASCOT) and secondary prevention cohorts (CARE and PROVE IT-TIMI 22).[7]
↑Szpirer C, Riviere M, Cortese R, Nakamura T, Islam MQ, Levan G, Szpirer J (June 1992). "Chromosomal localization in man and rat of the genes encoding the liver-enriched transcription factors C/EBP, DBP, and HNF1/LFB-1 (CEBP, DBP, and transcription factor 1, TCF1, respectively) and of the hepatocyte growth factor/scatter factor gene (HGF)". Genomics. 13 (2): 293–300. doi:10.1016/0888-7543(92)90245-N. PMID1535333.
↑ 2.02.1Vaxillaire M, Boccio V, Philippi A, Vigouroux C, Terwilliger J, Passa P, Beckmann JS, Velho G, Lathrop GM, Froguel P (April 1995). "A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q". Nature Genetics. 9 (4): 418–23. doi:10.1038/ng0495-418. PMID7795649.
↑Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR (October 1987). "Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters". Science. 238 (4827): 688–92. doi:10.1126/science.3499668. PMID3499668.
↑ 6.06.16.2Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (October 2003). "Genetic cause of hyperglycaemia and response to treatment in diabetes". Lancet. 362 (9392): 1275–81. doi:10.1016/S0140-6736(03)14571-0. PMID14575972.
↑ 9.09.1Chi YI, Frantz JD, Oh BC, Hansen L, Dhe-Paganon S, Shoelson SE (November 2002). "Diabetes mutations delineate an atypical POU domain in HNF-1alpha". Molecular Cell. 10 (5): 1129–37. doi:10.1016/s1097-2765(02)00704-9. PMID12453420.
↑ 10.010.110.2Narayana N, Phillips NB, Hua QX, Jia W, Weiss MA (September 2006). "Diabetes mellitus due to misfolding of a beta-cell transcription factor: stereospecific frustration of a Schellman motif in HNF-1alpha". Journal of Molecular Biology. 362 (3): 414–29. doi:10.1016/j.jmb.2006.06.086. PMID16930618.
↑D'Angelo A, Bluteau O, Garcia-Gonzalez MA, Gresh L, Doyen A, Garbay S, Robine S, Pontoglio M (May 2010). "Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium". Development. 137 (9): 1573–82. doi:10.1242/dev.044420. PMID20388655.
↑von Wnuck Lipinski K, Sattler K, Peters S, Weske S, Keul P, Klump H, Heusch G, Göthert JR, Levkau B (February 2016). "Hepatocyte Nuclear Factor 1A Is a Cell-Intrinsic Transcription Factor Required for B Cell Differentiation and Development in Mice". Journal of Immunology. 196 (4): 1655–65. doi:10.4049/jimmunol.1500897. PMID26800876.
↑Gu N, Adachi T, Matsunaga T, Takeda J, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K (August 2006). "Mutant HNF-1alpha and mutant HNF-1beta identified in MODY3 and MODY5 downregulate DPP-IV gene expression in Caco-2 cells". Biochemical and Biophysical Research Communications. 346 (3): 1016–23. doi:10.1016/j.bbrc.2006.06.010. PMID16781669.
↑Gu N, Tsuda M, Matsunaga T, Adachi T, Yasuda K, Ishihara A, Tsuda K (December 2008). "Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1alpha in epithelial intestinal cells". Clinical and Experimental Pharmacology & Physiology. 35 (12): 1433–9. doi:10.1111/j.1440-1681.2008.05015.x. PMID18671716.
↑Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M (April 2001). "Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism". Nature Genetics. 27 (4): 375–82. doi:10.1038/86871. PMID11279518.
↑Bluteau O, Jeannot E, Bioulac-Sage P, Marqués JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C, Laurent-Puig P, Zucman-Rossi J (October 2002). "Bi-allelic inactivation of TCF1 in hepatic adenomas". Nature Genetics. 32 (2): 312–5. doi:10.1038/ng1001. PMID12355088.
↑Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB (January 2009). "A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary". The American Journal of Surgical Pathology. 33 (1): 14–21. doi:10.1097/PAS.0b013e3181788546. PMID18830127.
↑Offman SL, Longacre TA (September 2012). "Clear cell carcinoma of the female genital tract (not everything is as clear as it seems)". Advances in Anatomic Pathology. 19 (5): 296–312. doi:10.1097/PAP.0b013e31826663b1. PMID22885379.
↑Owen KR (June 2016). "Treating young adults with type 2 diabetes or monogenic diabetes". Best Practice & Research. Clinical Endocrinology & Metabolism. 30 (3): 455–67. doi:10.1016/j.beem.2016.05.002. PMID27432078.
↑Zhou K, Pedersen HK, Dawed AY, Pearson ER (June 2016). "Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery". Nature Reviews. Endocrinology. 12 (6): 337–46. doi:10.1038/nrendo.2016.51. PMID27062931.
↑ 28.028.128.228.3Soutoglou E, Papafotiou G, Katrakili N, Talianidis I (April 2000). "Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins". The Journal of Biological Chemistry. 275 (17): 12515–20. doi:10.1074/jbc.275.17.12515. PMID10777539.
↑Ban N, Yamada Y, Someya Y, Miyawaki K, Ihara Y, Hosokawa M, Toyokuni S, Tsuda K, Seino Y (May 2002). "Hepatocyte nuclear factor-1alpha recruits the transcriptional co-activator p300 on the GLUT2 gene promoter". Diabetes. 51 (5): 1409–18. doi:10.2337/diabetes.51.5.1409. PMID11978637.
↑Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3: 89. doi:10.1038/msb4100134. PMC1847948. PMID17353931.
↑Rufibach LE, Duncan SA, Battle M, Deeb SS (July 2006). "Transcriptional regulation of the human hepatic lipase (LIPC) gene promoter". Journal of Lipid Research. 47 (7): 1463–77. doi:10.1194/jlr.M600082-JLR200. PMID16603721.
↑ 34.034.1Bulla GA, Kraus DM (December 2004). "Dissociation of the hepatic phenotype from HNF4 and HNF1alpha expression". Bioscience Reports. 24 (6): 595–608. doi:10.1007/s10540-005-2794-8. PMID16158197.
Further reading
Eastman Q, Grosschedl R (April 1999). "Regulation of LEF-1/TCF transcription factors by Wnt and other signals". Current Opinion in Cell Biology. 11 (2): 233–40. doi:10.1016/S0955-0674(99)80031-3. PMID10209158.
Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J (May 2007). "Genotype phenotype classification of hepatocellular adenoma". World Journal of Gastroenterology. 13 (19): 2649–54. doi:10.3748/wjg.v13.i19.2649. PMID17569132.